logo

For the Inventor, By the Inventor

Paris, France

Hybrigenics S.a.


USPTO Granted Patents = 10

% Expired Patents = 80.0



Trademarks = 3

Forward Citations = 41

Loading Chart...
Loading Chart...

25 inventors (with patents filed for the assignee):

goldMedal Rémi Delansorne (5 out of 5 patents)

silverMedal Frédéric Colland (4 out of 6 patents)

bronzeMedal Jean-Christophe Rain (4 out of 13 patents)

4.  Philippe Guedat (3 out of 13 patents)

5.  Etienne Formstecher (3 out of 3 patents)

6.  Xavier Jacq (3 out of 3 patents)

7.  Laurent Daviet (3 out of 3 patents)

8.  Guillaume Boissy (2 out of 2 patents)

9.  Catherine Borg-Capra (2 out of 2 patents)

10.  Matteo Colombo (2 out of 2 patents)

11.  Susan Benjamin (1 out of 1 patent)

12.  Cécile Planquette (1 out of 1 patent)

13.  Marie-Edith Gourdel (1 out of 3 patents)

14.  Roman Lopez (1 out of 1 patent)

15.  Frederic Colland (1 out of 1 patent)


10 patents:

1. 10478497 - Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer (2019-11-19),
2. 9546150 - Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7 (2017-01-17),
3. 9328093 - Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications (2016-05-03),
4. 9315455 - Process for isomerizing fused bicyclic structures and preparation of vitamin D analogs comprising the same (2016-04-19),
5. 9314474 - Formulations of 14-epi-analogues of vitamin D (2016-04-19),
6. 8648076 - Cysteine protease inhibitors and their therapeutic applications (2014-02-11),
7. 8481514 - Therapeutical uses of inecalcitol (2013-07-09),
8. 7875613 - Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications (2011-01-25),
9. 7462615 - Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications (2008-12-09),
10. 6916615 - Collection of prokaryotic DNA for two hybrid systems Helicobacter pylori protein-protein interactions and application thereof (2005-07-12),
Company Overview
Hybrigenics S.A. is a biopharmaceutical company based in Paris, France, specializing in the development of innovative therapies for the treatment of cancer and other serious diseases. The company focuses on the discovery and commercialization of small molecules that target specific cellular pathways, particularly those involved in cell division and survival. With a strong emphasis on research and development, Hybrigenics aims to advance its proprietary technologies to address unmet medical needs in oncology and related fields.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

10 Patents

#362 in Paris

#1,710 in France

#55,986 in the World

Paris, FR
Paris, France

Hybrigenics S.a.

Forward Citations = 41

25 inventors:

goldMedal Rémi Delansorne (5 out of 5 patents)

silverMedal Frédéric Colland (4 out of 6 patents)

bronzeMedal Jean-Christophe Rain (4 out of 13 patents)

4.  Philippe Guedat (3 out of 13 patents)

5.  Etienne Formstecher (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Hybrigenics S.a.. Retrieved from https://idiyas.com/company/hybrigenics-s-a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…